Ian Gilron

TL;DR: Previous studies suggest that 2‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole‐proprionic acid (AMPA)/kainate antagonists reduce experimentally induced pain and there have been no studies of AMPA/kainates antagonists in clinical pain.

TL;DR: Larger trials are needed to more precisely estimate the effect of topiramate in trigeminal neuralgia, and a multiple crossover design provides more information, which is important in conditions associated with considerable pain fluctuation.

TL;DR: The results suggest the possibility that, at least in some disease processes, excluding patients with a highly variable baseline 7‐day diary has the potential to improve the assay sensitivity of these analgesic clinical trials, although reductions of external validity must be considered when increasing the homogeneity of the investigated sample.

TL;DR: Gabapentin and pregabalin for the treatment of neuropathic pain: A review of laboratory and clinical evidence.

TL;DR: The role of early phase clinical trials, including pharmacokinetic-pharmacodynamic (PK-PD) trials, and the value of including both placebo and active standards of comparison in acute pain trials are discussed.